Purification that powers progress.
We believe that innovation in purification can unlock breakthroughs in medicine. By reimagining chromatography with scalable, high-performance membranes, we’re helping biopharma teams deliver therapies that improve lives around the world. Better purification means better outcomes.
Founded by Drs. Scott Husson and Jinxiang Zhou in 2013, in Greenville, South Carolina, the idea for the company was inspired by research from over a decade of investigation at Clemson University.
In 2022, Purilogics™ and its Purexa™ product portfolio became a part of Donaldson Company, Inc. (NYSE: DCI), a leading worldwide provider of innovative filtration products and solutions.
Now a Donaldson Life Sciences brand, Purexa products feature industry-leading membrane technologies for the rapidly growing biopharmaceutical industry. Our proprietary products are designed for use in rapid drug purification, from research to manufacturing grade.
Our Story
The newly defined Donaldson Life Sciences division is building a portfolio of biopharma innovations to provide cutting-edge technologies that simplify and accelerate development and production of therapeutics.
Donaldson Life Sciences combines 100 years of engineering excellence with modern bioprocessing technologies to help solve critical manufacturing challenges that stand between breakthrough science and the people who need it.
Drawing on more than a century of filtration expertise, we deliver transformational purification and production solutions that advance viral vector, nucleic acid, and advanced biologics manufacturing. Our portfolio is built to deliver efficiency and reliability at every step of your process.
Backed by Donaldson’s global footprint and trusted service, we’re committed to helping scientists bring impactful therapies to the world. Life Science evolves, Donaldson solves.